TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations
ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 449,000 | $25,045,220 | -34% | 0.03% |
| 2. | Ranger Investment Management Conrad Doenges (Cio) | 150,325 | $8,385,129 | 0.79% | |
| 3. | Rhenman & Partners Asset Management Henrik Rhenman | 90,500 | $5,048,090 | +1711% | 0.56% |
| 4. | Dorset Management David M. Knott | 59,839 | $3,337,819 | -11% | 1.83% |
| 5. | Navellier & Associates Louis Navellier | 29,290 | $1,633,796 | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | $1,013,000.00 | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | $95,760.00 | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | $351,750.00 | 12,878,185 | 2019-06-26 | Filing | |
| $6.53 | 114,855 | $750,003.15 | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | $34,300.00 | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $54.96 | 5,000 | $274,800.00 | 168,640 | 2026-09-10 | Filing | |
| $32.57 | 5,000 | $162,850.00 | 223,816 | 2025-11-24 | Filing | |
| $32.24 | 20,852 | $672,268.48 | 94,061 | 2025-09-11 | Filing | |
| $36.94 | 10,000 | $369,400.00 | 228,816 | 2025-06-13 | Filing | |
| $28.53 | 10,021 | $285,939.21 | 660,611 | 2025-01-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,703,676 | $206,627,503 | 0.01% | |
| 2. | 2,606,516 | $145,391,462 | 0.94% | |
| 3. | 2,423,794 | $135,199,230 | 0.03% | |
| 4. | 1,602,568 | $89,391,243 | 0.08% | |
| 5. | 1,464,496 | $81,689,587 | 0.02% |
News See All
10 Best Performing American Stocks in June 2026
In this article, we will look at the 10 Best Performing American Stocks in June 2026.
Is TG Therapeutics, Inc. (TGTX) A Good Stock To Buy Now?
Is TGTX a good stock to buy? We came across a bullish thesis on TG Therapeutics, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on TGTX.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2026 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2026 Earnings Call Transcript May 6, 2026TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is $0.12 EPS, expectations were $0.23.
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX)
TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 26, TG Therapeutics Inc.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the 13 Most Profitable Growth Stocks to Buy Right Now. Alec Stranahan of Bank of America reaffirmed a Sell rating on TG Therapeutics, Inc.
13 Most Profitable Growth Stocks to Buy Right Now
Equity markets remain volatile amid geopolitical uncertainties.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript February 26, 2026 Operator: Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2025 Earnings Call.
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025
TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best cheap biotech stocks to buy now. TG Therapeutics, Inc. (NASDAQ:TGTX) released financial results for fiscal Q4 and full year 2025 on February 26.